our current active studies

• Sponsor: Cerevance
• General Summary of Trial: Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson’s Disease Patients with Motor Complications
• Study Drug: Adjunctive therapy, a non-Dopaminergic, G-Protein Coupled Receptor (GPR6), inverse agonist also called, Solengepras. It’s a tablet that is orally administered every day.
• Looking to target: Patients with PD that experience OFF periods/motor complications.
• Length 16-21 weeks of participation
• 30 y/o , no DBS patients

• Sponsor: AbbVie
• General Summary: A Global Real-World Evidence Study on the long-term effectiveness of ABBV-951 in Advanced Parkinson´s Disease in routine clinical practice (ROSSINI: Real-world Outcomes with continuous Subcutaneous levodopa Infusion)
• Study Product: Continuous SC Apomorphine Infusion, administering Levadopa
• Targeting: Pts with advanced PD, that experience motor complications/OFF periods and dyskinesia everyday
• 18 y/o or older, DBS patients are welcome
• Length: 3+ years
   

 This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 65 years and older with Parkinson's disease and Parkinsonism with 2 years of follow-up. A total of 3,500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging. For more details go here.